Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2002-3-4
pubmed:abstractText
Inflammatory bowel disease (IBD) is a chronic, debilitating disorder of uncertain and perhaps multiple etiologies. It is believed to be due in part to disregulation of the immune system. Neuroimmune interactions may be involved in induction or maintenance of IBD. In the present study, we examined the potential role of a neurotransmitter, substance P, in a mouse model of IBD. We found that binding sites for substance P, and more specifically, neurokinin-1 receptors, were upregulated in intestinal tissue of mice with IBD-like syndrome. Dosing of mice with LY303870, a neurokinin-1 receptor antagonist, reduced the severity of IBD, and treatment of mice with preexisting IBD allowed partial healing of lesions. We hypothesize that blocking the binding of substance P to the neurokinin-1 receptor interrupts the inflammatory cascade that triggers and maintains intestinal lesions of IBD.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-10229849, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-10647043, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-10940277, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-11128483, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-1500156, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-15338912, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-1689696, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-2419545, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-2435473, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-6383937, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-7473161, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-7508124, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-7529913, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-7531101, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-7593747, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-7683320, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-7684884, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-8613403, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-8638732, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-8683123, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-8745057, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-8760824, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-8769871, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-8781237, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-8824334, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-8964902, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-9023291, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-9036982, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-9143232, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-9175155, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-9175156, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-9194827, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-9286220, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-9541482, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-9581804, http://linkedlifedata.com/resource/pubmed/commentcorrection/11874873-9846962
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1071-412X
pubmed:author
pubmed:issnType
Print
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
333-40
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Treatment with neurokinin-1 receptor antagonist reduces severity of inflammatory bowel disease induced by Cryptosporidium parvum.
pubmed:affiliation
Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, Iowa 50011, USA. ioana@iastate.edu
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't